Close

AbbVie's (ABBV) Venetoclax Combo Granted FDA Breakthrough Therapy Designation for r/r CLL

January 20, 2016 8:31 AM EST Send to a Friend
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for venetoclax in combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login